Dogwood Therapeutics Inc. (DWTX)
5.64
-0.23 (-3.92%)
At close: Apr 24, 2025, 3:59 PM
5.70
1.05%
After-hours: Apr 24, 2025, 07:58 PM EDT
-3.92% (1D)
| Bid | 5.59 |
| Market Cap | 10.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.35M |
| EPS (ttm) | -13.46 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.78 |
| Volume | 485,702 |
| Avg. Volume (20D) | 2,145,957 |
| Open | 6.05 |
| Previous Close | 5.87 |
| Day's Range | 5.55 - 6.18 |
| 52-Week Range | 1.62 - 29.28 |
| Beta | 2.01 |
About DWTX
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, att...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 12
Stock Exchange NASDAQ
Ticker Symbol DWTX
Website https://www.dwtx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for DWTX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 77.30% from the latest price.
Stock Forecasts1 month ago
-27.76%
Dogwood Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
1 month ago
+48.98%
Dogwood Therapeutics shares are trading higher as traders circulate a newsletter mention.